Stock News•2 weeks ago
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
Merck's ENFLONSIA sBLA was accepted by the FDA to expand its RSV LRTD indication to children under two at increased risk for severe disease through their second season, potentially broadening the drug...
